Entering text into the input field will update the search result below

Annovis: Novel Approach To Dementia

Apr. 03, 2021 6:26 PM ETAnnovis Bio, Inc. (ANVS)6 Comments


  • Annovis is a nano cap that went up recently after announcing positive interim data from its phase 2a trial.
  • They will announce complete data by July.
  • The company is very low in cash.
  • Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »

Abstract brain activity image
Photo by gremlin/E+ via Getty Images

Annovis (NYSE:ANVS) is an early stage nanocap biopharma targeting a number of major neurodegenerative diseases through what looks like a novel mechanism of action based on well-researched theories. The company is developing drugs

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-

Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. 

This article was written by

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.

They lead the investing group Total Pharma Tracker where they offer a monthly updated catalyst database, an investability scoring system for quick reference ideas, and direct access in chat for dialogue and questions. Learn more.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (6)

TraderLawJF profile picture
AD data expected this month? Still bullish?
Suncitybill1 profile picture
The company filed a prospectus to sell $250,000,000 worth of common, warrants, or Preferred Stock on 2/1/2021. They always knew that they would need additional funds to pay for a Phase 3 trial. At the beginning of February, the stock moved up sharply; I presume that they are waiting for the average selling price for thirty days to be in the high twenties to complete the offering.
Last February, when I first purchased shares, it was one of the four companies with programs that looked like they had a real chance to break-thru on PD and Dementia. Two still look very promising, the third was bought out, and the fourth failed. Annovis Bio has management that has a large amount of their own money invested in the company.
NAMAKAN profile picture
The market cap seems far too low in comparison to the results of the catalysts. Should be at least 300 million..
...If they get decent phase 2 at least 500 million which would still be 1/3 of SAVA..
biogenius profile picture
I looked at the company and agree with most of what you said.
1. This company should be worth a lot more even if it is good for only PD and not AD.
2. This company needs cash.
3. I was impressed when the press release said the statistic outcome was positive for both the baseline and the placebo. However, when I look at slide 18 of the company presentation, I think the outcome comes from the fact that the placebo got worse. That should be expected except that the subjects were retested in only 25 days and I am not sure if the placebo subjects should deteriorate that fast. I am not saying that the result is invalid. I am just having second thoughts, that is all.
nikit2h profile picture
@biogenius "The statistical outcome difference was true whether the outcome was compared with baseline or with placebo."
biogenius profile picture
I saw that and as I said, I was impressed. However, when I looked at that slide 18, the reason why the difference was significant is because the patients on placebo deteriorated a lot in 25 days. My point is that PD, as a neurodegenerative disease, tend not to deteriorate that fast. At least the people that I know with AD don't change that much in 25 days. I am not saying that the result is wrong, I am just putting a question mark in my head.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About ANVS

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ANVS

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.